Ferraris Joan D, Persaud Prita, Williams Chester K, Chen Ye, Burg Maurice B
Laboratory of Kidney and Electrolyte Metabolism, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16800-5. doi: 10.1073/pnas.222659799. Epub 2002 Dec 13.
Hypertonicity-induced increase in activity of the transcription factor tonicity-responsive enhancer/osmotic response element-binding protein (TonEBP/OREBP) protects renal cells by increasing transcription of genes, including those involved in increased accumulation of organic osmolytes. We previously showed that hypertonicity increases transactivating activity of TonEBP/OREBP. Assay with a binary GAL4 transactivation system showed that the 984 C-terminal amino acids of TonEBP/OREBP (amino acids 548-1531) contain a tonicity-dependent transactivation domain (TAD). Also, amino acids 548-1531 undergo tonicity-dependent phosphorylation, and some inhibitors of protein kinases reduce the tonicity-dependent transactivation. In the present studies we examined the role of protein kinase A (PKA).
(i) An inhibitor of PKA (H89) reduces tonicity-dependent increases in transactivation, ORE/TonE reporter activity, and induction of aldose reductase and betaine transporter mRNAs. (ii) Overexpression of the catalytic subunit of PKA (PKAc) increases transactivation activity of amino acids 548-1531 and activity of an ORE/TonE reporter. The increases are much greater under isotonic than under hypertonic conditions. (iii) A dominant-negative PKAc reduces activity of an ORE/TonE reporter. (iv) PKAc activity increases with tonicity but cAMP does not. (v) TonEBP/OREBP and PKAc coimmunoprecipitate. (vi) amino acids 872-1271, including N- and C-terminal polyglutamine stretches, demonstrate tonicity-dependent transactivation, albeit less than amino acids 548-1531, and a similar role for PKA.
(i) PKA plays an important role in TonEBP/OREBP activation of tonicity-dependent gene expression; (ii) PKA activation of TonEBP/OREBP appears to be cAMP-independent; and (iii) amino acids 872-1271 are sufficient for tonicity-dependent transactivation of TonEBP/OREBP.
高渗诱导的转录因子渗透压反应增强子/渗透压反应元件结合蛋白(TonEBP/OREBP)活性增加,通过增加包括参与有机渗透物积累增加的基因转录来保护肾细胞。我们之前表明高渗会增加TonEBP/OREBP的反式激活活性。使用二元GAL4反式激活系统的检测表明,TonEBP/OREBP的984个C末端氨基酸(第548 - 1531位氨基酸)包含一个渗透压依赖性反式激活结构域(TAD)。此外,第548 - 1531位氨基酸会发生渗透压依赖性磷酸化,并且一些蛋白激酶抑制剂会降低渗透压依赖性反式激活。在本研究中,我们研究了蛋白激酶A(PKA)的作用。
(i)PKA抑制剂(H89)可降低渗透压依赖性的反式激活增加、ORE/TonE报告基因活性以及醛糖还原酶和甜菜碱转运体mRNA的诱导。(ii)PKA催化亚基(PKAc)的过表达增加了第548 - 1531位氨基酸的反式激活活性以及ORE/TonE报告基因的活性。在等渗条件下的增加比在高渗条件下大得多。(iii)显性负性PKAc降低了ORE/TonE报告基因的活性。(iv)PKAc活性随渗透压增加,但cAMP不增加。(v)TonEBP/OREBP和PKAc可共免疫沉淀。(vi)包括N末端和C末端多聚谷氨酰胺序列的第872 - 1271位氨基酸表现出渗透压依赖性反式激活,尽管比第548 - 1531位氨基酸弱,并且PKA起类似作用。
(i)PKA在TonEBP/OREBP激活渗透压依赖性基因表达中起重要作用;(ii)PKA对TonEBP/OREBP的激活似乎不依赖cAMP;(iii)第872 - 1271位氨基酸足以实现TonEBP/OREBP的渗透压依赖性反式激活。